459 related articles for article (PubMed ID: 28072717)
21. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma.
McLean N; Tighiouart M; Muller S
Oral Oncol; 2008 Nov; 44(11):1039-46. PubMed ID: 18396446
[TBL] [Abstract][Full Text] [Related]
22. Mucosal melanoma of the cranio-facial region: Surgical challenges and therapeutic options.
Thierauf J; Glück AM; Plinkert P; Veit JA; Hoffmann TK; Körber A; Bergmann C
Auris Nasus Larynx; 2019 Apr; 46(2):252-259. PubMed ID: 30082161
[TBL] [Abstract][Full Text] [Related]
23. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
25. Anorectal melanoma: experience from a tertiary cancer care centre in South India.
Ranjith S; Muralee M; Sajeed A; Arun PM; Cherian K; Nair CK; Augustine P; Ahamed I
Ann R Coll Surg Engl; 2018 Mar; 100(3):185-189. PubMed ID: 29046101
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
27. A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Knowles J; Lynch AC; Warrier SK; Henderson M; Heriot AG
Colorectal Dis; 2016 Sep; 18(9):877-82. PubMed ID: 26546509
[TBL] [Abstract][Full Text] [Related]
28. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
30. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
31. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Hallmeyer S; Gonzalez R; Lawson DH; Cranmer LD; Linette GP; Puzanov I; Taback B; Cowey CL; Ribas A; Daniels GA; Moore T; Gibney GT; Tawbi H; Whitman E; Lee G; Mun Y; Liu S; Hamid O
Melanoma Res; 2017 Dec; 27(6):585-590. PubMed ID: 29076950
[TBL] [Abstract][Full Text] [Related]
33. Optimizing local control in anorectal melanoma.
Ramakrishnan AS; Mahajan V; Kannan R
Indian J Cancer; 2008; 45(1):13-9. PubMed ID: 18453735
[TBL] [Abstract][Full Text] [Related]
34. Update on primary mucosal melanoma.
Tacastacas JD; Bray J; Cohen YK; Arbesman J; Kim J; Koon HB; Honda K; Cooper KD; Gerstenblith MR
J Am Acad Dermatol; 2014 Aug; 71(2):366-75. PubMed ID: 24815565
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
37. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
38. Second primary melanoma on a patient undergoing vemurafenib therapy. A case report.
Onnis G; Palmieri G; Montesu MA; Satta R
Int J Dermatol; 2017 Jul; 56(7):792-794. PubMed ID: 28345133
[TBL] [Abstract][Full Text] [Related]
39. Mucosal melanomas.
Tomicic J; Wanebo HJ
Surg Clin North Am; 2003 Apr; 83(2):237-52. PubMed ID: 12744608
[TBL] [Abstract][Full Text] [Related]
40. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.
Chang AE; Karnell LH; Menck HR
Cancer; 1998 Oct; 83(8):1664-78. PubMed ID: 9781962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
